Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer

Fig. 1

Establishment and characterization of pancreatic tumor organoids derived from primary and metastatic PDAC tissue specimens. A. Information about sampling sites and confirmed mutations in PDAC PDO lines. Shown are mutations confirmed by the ClinVar and COSMIC databases. See also Table S1. B. Histological characterization of pancreatic cancer PDOs. Shown are selected examples of specimens of primary tissues (left: HE-stained) and established organoids (middle: bright field, right: HE-stained). Scale bar, 100 μm. C. PCR microarray analysis of the expression of cancer stem cell genes in pancreatic cancer cell lines and PDOs. D. Western blotting analysis of CD133/PROM1, SOX2, CD24, CA19–9 in pancreatic cancer cell lines and PDOs. E. Flow cytometry analysis of PDOs. Histogram: CD44 (X-axis), cell count (Y-axis)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us